In cancer, considered to be a Th2-dominant disease with excess of IL-4, IL-5, IL-10, and TGF-β production, a therapeutically driven shift back toward the Th1 profile is of interest, as it might correlate with immune and perhaps clinical recovery (Lucey et al., 1996). This evidence concerns the gene IL10 and cancer.